- Conditions
- HNSCC
- Interventions
- Cesium-131, Pembrolizumab
- Device · Drug
- Lead sponsor
- University of Cincinnati
- Other
- Eligibility
- 19 Years to 90 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 2
- States / cities
- Cincinnati, Ohio • Philadelphia, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 241–264
of 447
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes
- Interventions
- Fludarabine Phosphate, Tacrolimus, Thiotepa, Total-Body Irradiation (TBI), Magnetic Affinity Cell Sorting, Peripheral Blood Stem Cell Transplantation, Allogeneic Hematopoietic Stem Cell Transplantation, T Cell-Depleted Hematopoietic Stem Cell Transplantation
- Drug · Radiation · Other + 2 more
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 14 Years to 55 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2020
- U.S. locations
- 2
- States / cities
- New Haven, Connecticut • Seattle, Washington
- Conditions
- Glycogen Storage Disease
- Interventions
- mRNA-3745
- Drug
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 8
- States / cities
- Farmington, Connecticut • Boston, Massachusetts • Durham, North Carolina + 4 more
- Conditions
- Breast Cancer
- Interventions
- high performance liquid chromatography, laboratory biomarker analysis, mass spectrometry, medical chart review
- Other
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years and older · Female only
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2012
- U.S. locations
- 2
- States / cities
- Rochester, Minnesota • Omaha, Nebraska
- Conditions
- Neuromyelitis Optica
- Interventions
- Rituximab
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 12 Years to 86 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2010
- U.S. locations
- 2
- States / cities
- San Francisco, California • Columbia University Medical Center 710 West 168th Street,, New York
- Conditions
- Acute Decompensated Heart Failure
- Interventions
- Reprieve System, furosemide infusion
- Device · Drug
- Lead sponsor
- Reprieve Cardiovascular, Inc
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 35
- States / cities
- Irvine, California • Long Beach, California • Sacramento, California + 28 more
- Conditions
- Metastatic Cancer, Breast Cancer, Lobular Breast Carcinoma
- Interventions
- 18F-fluorofuranylnorprogesterone, Liquid Biopsy, Positron Emission Tomography/Computed Tomography
- Drug · Device
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Age-Related Macular Degeneration, Choroidal Neovascularization
- Interventions
- Intravenous Daclizumab, Intravenous Infliximab, Observation, Oral Rapamycin
- Drug · Other
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 55 Years to 92 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Hyponatremia
- Interventions
- 0.9 Normal Saline, 0.45 Normal Saline
- Other
- Lead sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
- Other
- Eligibility
- 6 Months to 16 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Labor Complication
- Interventions
- Continue Oxytocin, Discontinue Oxytocin
- Drug · Other
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- Female only
- Enrollment
- 400 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Metastatic Prostate Cancer, Cancer of the Prostate, Prostate Cancer
- Interventions
- Anti-OX40, Radiation, Cyclophosphamide
- Drug · Radiation
- Lead sponsor
- Providence Health & Services
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Myelofibrosis, MDS, Refractory Anemia, Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Non-Hodgkin's Lymphoma, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes
- Interventions
- filgrastim, cyclophosphamide, cyclosporine, fludarabine phosphate, mycophenolate mofetil, umbilical cord blood transplantation, total-body irradiation
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Up to 55 Years
- Enrollment
- 213 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2019
- U.S. locations
- 2
- States / cities
- Minneapolis, Minnesota • Seattle, Washington
- Conditions
- Colorectal Cancer
- Interventions
- cholecalciferol, polymerase chain reaction, polymorphism analysis, protein expression analysis, reverse transcriptase-polymerase chain reaction, western blotting, high performance liquid chromatography, laboratory biomarker analysis, pharmacological study, adjuvant therapy, immunoscintigraphy
- Dietary Supplement · Genetic · Other + 1 more
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Atherosclerosis
- Interventions
- BMS-962476, Placebo matching with BMS-962476
- Biological
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Traumatic Brain Injury (TBI) Patients
- Interventions
- Normal Saline (0.9% NaCl), balanced crystalloid
- Drug
- Lead sponsor
- University of Louisville
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Louisville, Kentucky
- Conditions
- Cancer, Leukemia, Myelodysplastic Syndrome, Non-Hodgkin's Lymphoma
- Interventions
- Fludarabine, Cyclophosphamide, Transplantation
- Drug · Procedure
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 4 Years to 50 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2015
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Alpha 1 Antitrypsin Deficiency
- Interventions
- Alpha-1 15%, Liquid Alpha1-PI
- Drug · Other
- Lead sponsor
- Grifols Therapeutics LLC
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 7 more
- Conditions
- Alcohol Withdrawal, Alcohol Abstinence, Alcohol Use Disorder
- Interventions
- Sodium Acetate, Placebo
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Pulmonary Alveolar Proteinosis, COPD, Idiopathic Pulmonary Fibrosis, Viral Pneumonia, Coronavirus Infection, Interstitial Lung Disease
- Interventions
- Microcannula Harvest Adipose Derived tissue stromal vascular fraction (tSVF), Centricyte 1000, IV Deployment Of cSVF In Sterile Normal Saline IV Solution, Liberase Enzyme (Roche), Sterile Normal Saline for Intravenous Use
- Procedure · Device · Drug
- Lead sponsor
- Black Tie Medical, Inc.
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Stevensville, Montana
- Conditions
- Multiple Myeloma
- Interventions
- belantamab mafodotin, Pembrolizumab
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia • Indianapolis, Indiana • Charlotte, North Carolina + 1 more
- Conditions
- Fibrodysplasia Ossificans Progressiva
- Interventions
- REGN2477, Matching placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 3
- States / cities
- Rochester, Minnesota • Philadelphia, Pennsylvania • Nashville, Tennessee
- Conditions
- Acute Lymphoblastic Leukemia, Acute Lymphoblastic Lymphoma
- Interventions
- Prednisone, Vincristine, Daunorubicin, Pegaspargase, Erwinase®, Cyclophosphamide, Cytarabine, Mercaptopurine, Dasatinib, Methotrexate, Blinatumomab, Ruxolitinib, Bortezomib, Dexamethasone, Doxorubicin, Etoposide, Clofarabine, Vorinostat, Idarubicin, Nelarabine, Thioguanine, Asparaginase Erwinia chrysanthemi (recombinant)-rywn, Calaspargase Pegol
- Drug
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 1 Year to 18 Years
- Enrollment
- 790 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2028
- U.S. locations
- 7
- States / cities
- Palo Alto, California • San Diego, California • Peoria, Illinois + 4 more
- Conditions
- Colorectal Cancer, Healthy, no Evidence of Disease, Precancerous Condition
- Interventions
- gene expression analysis, polymerase chain reaction, polymorphism analysis, protein expression analysis, proteomic profiling, gas chromatography, laboratory biomarker analysis, liquid chromatography, mass spectrometry, questionnaire administration
- Genetic · Other
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 551 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Anxiety Disorders and Symptoms, Fibromyalgia, Arthritis, Chronic Pain, Hypertension,Essential
- Interventions
- IV Vitamin Infused Therapy Treatment, Herbal medicine
- Dietary Supplement · Drug
- Lead sponsor
- Faith A. Richardson
- Other
- Eligibility
- 21 Years to 80 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Dover, Delaware